PROGRAM CHAIR
Joel M. Gelfand, MD, MSCE
James J Leyden Professor of Dermatology and Epidemiology
Vice Chair for Clinical Research and
Medical Director, Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
PROGRAM OVERVIEW
This MedGames activity is an online, interactive, gamification-style CME activity that covers important topics in psoriasis. The educational format of this program is engaging and covers the diagnosis of psoriasis, its impact on patients, and clinical data regarding the efficacy and safety of current and emerging treatments for this disease.
TARGET AUDIENCE
This educational activity is designed for US-based dermatologists and other healthcare professionals involved in the management of patients with psoriasis.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Assess patients with plaque psoriasis for disease severity and response to therapy
- Compare the benefits and risks of IL-23 inhibitors with other biologics for the management of plaque psoriasis
- Incorporate evidence-based research and guidelines into the selection of treatment options
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: this program would be beneficial for nurses involved in the care of patients with plaque psoriasis.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty Member | Disclosure |
| Joel M. Gelfand, MD, MSCE | Dr. Gelfand has served as a consultant (with honoraria) for Abbvie, BMS, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies), GSK, Happify, Lilly (DMC), Leo, Janssen Biologics, Novartis Corp, Pfizer, UCB (DSMB), Neuroderm (DSMB), and Mindera Dx; receives research grants (to Trustees of the University of Pennsylvania) from Amgen, Boehringer Ingelheim, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis supported indirectly by pharmaceutical sponsors. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. He is a deputy editor for the Journal of Investigative Dermatology (receiving honoraria from the Society for Investigative Dermatology), is chief medical editor for Healio Psoriatic Disease (receiving honoraria), and is a member of the Board of Directors for the International Psoriasis Council (receiving no honoraria). |
CME content review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE content review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM—Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff planners and managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright ©2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
